Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab175611-100μg
|
100μg |
10
|
$39.90
|
|
|
Ab175611-1mg
|
1mg |
4
|
$199.90
|
|
|
Ab175611-5mg
|
5mg |
1
|
$489.90
|
|
|
Ab175611-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$709.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Natalizumab (anti-ITGA4) - Primary antibody, specific to ITGA4, Human IgG4, Antibody of integrin α4β1;Antibody of integrin; alpha 4 subunit (antigen CD49D; alpha 4 subunit of VLA-4 receptor) |
|---|---|
| Synonyms | 269C wild type antibody | Antigen CD49D, alpha 4 subunit of VLA 4 receptor antibody | CD49 antigen like family member D antibody | CD49 antigen-like family member D antibody | CD49d antibody | IA4 antibody | Integrin alpha 4 antibody | Integrin alpha 4 su |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | ITGA4 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of integrin α4β1;Antibody of integrin; alpha 4 subunit (antigen CD49D; alpha 4 subunit of VLA-4 receptor) |
| Product Description |
Natalizumab (anti-ITGA4) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab (anti-ITGA4) can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab (anti-ITGA4) is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses. |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic acids and derivatives |
| Class | Carboxylic acids and derivatives |
| Subclass | Amino acids, peptides, and analogues |
| Intermediate Tree Nodes | Peptides |
| Direct Parent | Oligopeptides |
| Alternative Parents | Phenylalanine and derivatives Aspartic acid and derivatives Leucine and derivatives Methionine and derivatives N-acyl-alpha amino acids and derivatives Alpha amino acid amides Amphetamines and derivatives Dicarboxylic acids and derivatives N-acyl amines Tertiary carboxylic acid amides Primary carboxylic acid amides Secondary carboxylic acid amides Sulfenyl compounds Dialkylthioethers Carboxylic acids Organopnictogen compounds Hydrocarbon derivatives Carbonyl compounds Organonitrogen compounds Organic oxides |
| Molecular Framework | Aromatic homomonocyclic compounds |
| Substituents | Alpha-oligopeptide - Phenylalanine or derivatives - Methionine or derivatives - Aspartic acid or derivatives - Leucine or derivatives - N-acyl-alpha amino acid or derivatives - Alpha-amino acid amide - N-substituted-alpha-amino acid - Alpha-amino acid or derivatives - Amphetamine or derivatives - Fatty acyl - Benzenoid - Dicarboxylic acid or derivatives - Fatty amide - N-acyl-amine - Monocyclic benzene moiety - Tertiary carboxylic acid amide - Carboxamide group - Secondary carboxylic acid amide - Primary carboxylic acid amide - Dialkylthioether - Carboxylic acid - Sulfenyl compound - Thioether - Organopnictogen compound - Organic oxygen compound - Organic nitrogen compound - Carbonyl group - Hydrocarbon derivative - Organic oxide - Organosulfur compound - Organooxygen compound - Organonitrogen compound - Aromatic homomonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds. |
| External Descriptors | Not available |
|
|
|
| Isotype | Human IgG4 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 26.1 kDa (Light Chain) & 51.3 kDa (Heavy Chain), under reducing conditions; 192.7 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 189261-10-7 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Natalizumab (anti-ITGA4) (Ab175611) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling ITGA4 (red) with Natalizumab (anti-ITGA4) (Ab175611). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Natalizumab (anti-ITGA4) (Ab175611) - SEC
The purity of Natalizumab (anti-ITGA4) (Ab175611) is more than 95% verified by HPLC.
Natalizumab (anti-ITGA4) (Ab175611) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling ITGA4 (red) with Natalizumab (anti-ITGA4) (Ab175611). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Natalizumab (anti-ITGA4) (Ab175611) - Flow Cytometry
Flow Cytometry analysis of U937 cells labelling ITGA4 (red) with Natalizumab (anti-ITGA4) (Ab175611). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Natalizumab (anti-ITGA4) (Ab175611) - Flow Cytometry
Flow Cytometry analysis of HeLa cells labelling ITGA4 (red) with Natalizumab (anti-ITGA4) (Ab175611). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jun 07, 2024 | Ab175611 | |
| Certificate of Analysis | Jun 07, 2024 | Ab175611 | |
| Certificate of Analysis | Jun 07, 2024 | Ab175611 |